Table 3.
Cox Regression Analysis of Baseline Parameters and PSA-PFS
| Parameter | Univariate Cox regression, HR (95%CI) |
p-value | Multivariate Cox regression, HR (95%CI) |
p-value |
|---|---|---|---|---|
| PSMA-ligand PET parameters | ||||
| Number of lesions | 1.04 [0.93–1.15] | 0.529 | ||
| TTV | 0.99 [0.92–1.06] | 0.722 | ||
| ITLV | 0.97 [0.91–1.04] | 0.436 | ||
| Highest SUVmax | 0.68 [0.57–0.81] | < 0.001 | ||
| Whole-body SUVmax | 0.59 [0.47–0.74] | < 0.001 | 0.51 [0.4–0.66] | < 0.001 |
| Whole-body SUVmean | 0.60 [0.42–0.86] | 0.006 | ||
| Whole-body SUVpeak | 0.6 [0.47–0.76] | < 0.001 | ||
| Pretherapeutic clinical parameters | ||||
| Age | 0.96 [0.94–0.98] | < 0.001 | 0.98 [0.96–1.01] | 0.226 |
| Time since initial diagnosis | 0.8 [0.68–0.93] | 0.005 | 0.9 [0.74–1.09] | 0.266 |
| Prior chemotherapy | 1.68 [1.15–2.49] | 0.008 | 1.64 [1.07–2.58] | 0.028 |
| Liver metastases | 1.0 [0.52–1.74] | 0.986 | ||
| Visceral metastases | 0.80 [0.52–1.19] | 0.292 | ||
| PSA | 1.02 [0.96–1.09] | 0.543 | ||
| AP | 1.27 [1.09–1.47] | 0.002 | 1.09 [0.89–1.33] | 0.387 |
| LDH | 1.46 [1.18–1.76] | < 0.001 | 1.30 [0.98–1.69] | 0.056 |
| Hb | 0.50 [0.23–1.11] | 0.084 | ||
All continuous parameters except age and Hb were log (base2) transformed. Significant p-values are given in bold. PSA = prostate-specific antigen; PFS = progression-free survival; HR = hazard ratio; CI = confidence interval; PSMA = prostate-specific membrane antigen; PET = positron emission tomography; TTV = total tumor volume ITLV = intensity-weighted lesion volume; SUVmax = maximum standardized uptake value; SUVmean = mean standardized uptake value; SUVpeak = peak standardized uptake value; AP = alkaline phosphatase; LDH = lactate dehydrogenase; Hb = hemoglobin